“…Table 1 describes the summary of the 12 included studies that were published between 2010 and 2017. 15–26 There were 702 participants with an age range from 57.06 to 73.53 years. Among these included studies, two focused on the efficiency of subcutaneous BTX-A, 21,26 three focused on NB, 15–17 five studies focused on PRF therapy, 15,16,19–21 one study focused on PRF + NB, 17 one study focused on PRF + NB + SC, 19 three studies focused on SC, 23,24,26 one study focused on SC + NB, 24 one study focused on SC + NB + O3 injection, 24 and one study focused on SGB.…”